Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Loading live signals…
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Acquiring Company
Bristol-Myers Squibb Company
Acquired Company
Medarex
New YorkPrincetonBiotechnologyProfessional ServicesHealth CareMedicalTherapeuticsPharmaceuticalLegalBiopharmaLaw EnforcementBiotechnologyHealth CareTherapeuticsBiopharmaDescription
Bristol-Myers Squibb has acquired Medarex to enhance its cancer treatment capabilities. This acquisition is pivotal for the company's development pipeline, bringing a promising drug targeting melanoma. With this strategic move, Bristol-Myers aims to solidify its leadership in oncology and expand treatment options for various cancers.
Related People
M&A Insights
Based on deal dataIntegration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed